Blueprint Medicines Backtesting

BPMC -- USA Stock  

USD 62.29  1.55  2.43%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Blueprint Medicines Corporation and determine expected loss or profit from investing in Blueprint Medicines over given investment horizon. Check also Blueprint Medicines Hype Analysis, Blueprint Medicines Correlation, Blueprint Medicines Valuation, Blueprint Medicines Volatility as well as analyze Blueprint Medicines Alpha and Beta and Blueprint Medicines Performance.
 Time Horizon     30 Days    Login   to change
SymbolX
Backtest

Blueprint Medicines 'What if' Analysis

June 23, 2018
0.00
No Change 0.00  0.0%
In 30 days
July 23, 2018
0.00
If you would invest  0.00  in Blueprint Medicines on June 23, 2018 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corporation or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with China Cord, NantKwest, DelMar Pharmaceuticals, Denali Therapeutics, Dova Pharmaceuticals, Dicerna Pharmaceuticals, and DYNAVAX TECHNOLOG. Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that ta...

Blueprint Medicines Upside/Downside Indicators

Information Ratio0.23
Maximum Drawdown8.81
Value At Risk5.21
Potential Upside3.24
  

Blueprint Medicines Market Premium Indicators

Risk Adjusted Performance0.08
Jensen Alpha0.65
Total Risk Alpha1.12
Treynor Ratio0.32

Blueprint Medicines Backtested Returns

Macroaxis considers Blueprint Medicines to be not too volatile. Blueprint Medicines secures Sharpe Ratio (or Efficiency) of -0.004 which signifies that Blueprint Medicines had -0.004% of return per unit of risk over the last 1 month. Macroaxis philosophy towards foreseeing risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Blueprint Medicines Corporation exposes twenty-one different technical indicators which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Blueprint Medicines Risk Adjusted Performance of 0.08 and Mean Deviation of 1.88 to double-check risk estimate we provide. Macroaxis gives Blueprint Medicines performance score of 0 on a scale of 0 to 100. The firm shows Beta (market volatility) of 1.5219 which signifies that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform.. Even though it is essential to pay attention to Blueprint Medicines historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Blueprint Medicines Corporation exposes twenty-one different technical indicators which can help you to evaluate its performance. Blueprint Medicines has expected return of -0.0089%. Please be advised to confirm Blueprint Medicines Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to decide if Blueprint Medicines past performance will be repeated at some point in the near future.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation(0.69) 

Very good reverse predictability

Blueprint Medicines Corporation has very good reverse predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from June 23, 2018 to July 8, 2018 and July 8, 2018 to July 23, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines price movement. The serial correlation of -0.69 indicates that around 69.0% of current Blueprint Medicines price fluctuation can be explain by its past prices. Given that Blueprint Medicines Corporation has negative autocorrelation for selected time horizon, investors may consider taking a contrarian position regarding future price movement of Blueprint Medicines for similar time interval.
Correlation Coefficient -0.69
Spearman Rank Test -0.26
Price Variance 2.71
Lagged Price Variance 4.26

Blueprint Medicines lagged returns against current returns

 Current and Lagged Values 
      Timeline 

Blueprint Medicines regressed lagged prices vs. current prices

 Current vs Lagged Prices 
      Timeline 

Blueprint Medicines Lagged Returns

 Regressed Prices 
      Timeline 

Did you try this?

Run Portfolio Center Now
   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Portfolio Center

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Blueprint Medicines and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Blueprint Medicines Hype Analysis, Blueprint Medicines Correlation, Blueprint Medicines Valuation, Blueprint Medicines Volatility as well as analyze Blueprint Medicines Alpha and Beta and Blueprint Medicines Performance. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">